Piet Herdewijn

USPTO Granted Patents = 19 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 128(Granted Patents)

Location History:

Wezemaal, BE (2006 - 2016)
Rotselaar, BE (2009 - 2016)
Leuven, BE (2015 - 2017)
Heverlee, BE (2016 - 2021)

Company Filing History:

8 out of 84

K.u. Leuven Research & Development

patents

6 out of 238

Katholieke Universiteit Leuven, Ku Leuven R&d

patents

3 out of 1,648

Roche Diagnostics Operations, Inc.

patents

4. 2 out of 345

Katholieke Universiteit Leuven

where one patent can have more than one assignee

Years Active: 2006-2021

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11040047 - Prodrugs of nucleoside phosphonates (2021-06-22),

2. 10087209 - Antiviral compounds, a process for their preparation, and their use for treating viral infections (2018-10-02),

3. 9730944 - Antiviral activity of novel bicyclic heterocycles (2017-08-15),

4. 9522932 - Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (2016-12-20),

5. 9518066 - GAK modulators (2016-12-13),

6. 9301961 - Autoimmune and inflammatory disorder therapy (2016-04-05),

7. 9249177 - Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (2016-02-02),

8. 9221822 - Thiazolopyrimidine modulators as immunosuppressive agents (2015-12-29),

9. 9193741 - Antiviral activity of bicyclic heterocycles (2015-11-24),

10. 9139572 - Compounds, methods, complexes, apparatuses and uses relating to stabile forms of NAD/NADH (2015-09-22),

11. 8901132 - Thiazolopyrimidine modulators as immunosuppressive agents (2014-12-02),

12. 8809520 - Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (2014-08-19),

13. 8758688 - Microelectronic structures for patterned deposition of molecules onto surfaces (2014-06-24),

14. 8501709 - Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production (2013-08-06),

15. 8242087 - Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents (2012-08-14),

Title: Piet Herdewijn: Pioneering Antiviral Solutions Through Innovative Patents

Introduction:

Piet Herdewijn, hailing from Wezemaal, Belgium, is a prolific inventor and researcher in the field of medicine and antiviral therapies. With an impressive track record of 19 patents to his name, Herdewijn has played a significant role in advancing the treatment and prevention of viral infections. This article explores some of his latest patents, notable career highlights, collaborations, and the lasting impact of his groundbreaking innovations.

Latest Patents:

Piet Herdewijn's latest patents demonstrate his dedication to developing novel antiviral compounds and therapeutic approaches. Two of his recent patents are worth mentioning:

1. Prodrugs of Nucleoside Phosphonates:

This patent introduces phosphonoamidate prodrugs, presenting a significant advancement in antiviral treatment. The phosphonate-modified nucleosides described here are specifically designed to treat or prevent viral infections, particularly those caused by the herpes simplex virus, human cytomegalovirus, varicella-zoster virus, vaccinia virus, and adenovirus.

2. Antiviral Compounds and Their Preparation:

Herdewijn's groundbreaking research has led to the development of pro-drugs of L-2'-deoxythreose nucleoside phosphonates. These phosphoramidate, phosphorodiamidate, and phospho-diester pro-drugs hold great promise in combating viral infections, specifically those belonging to the HBV family.

Career Highlights:

Throughout his career, Piet Herdewijn has made substantial contributions to the field of antiviral research. Notably, he has been associated with renowned institutions such as KU Leuven Research & Development (formerly Katholieke Universiteit Leuven) and KU Leuven R&D.

Herdewijn's dedication and expertise have led to several breakthroughs in antiviral therapies, enhancing our ability to treat and prevent infections caused by various viruses. His patents and research findings have paved the way for the development of new medicines and therapeutic strategies, significantly impacting the medical community.

Collaborations:

Collaboration stands as an essential element in Piet Herdewijn's career, allowing him to maximize his research potential and contribute to numerous innovative projects. Notably, he has worked closely with esteemed researchers Christophe Pannecouque and Steven De Jonghe, who have played significant roles in various projects alongside Herdewijn.

These collaborations have facilitated the exchange of ideas, expertise, and resources, leading to greater scientific advancements and, ultimately, the development of improved antiviral therapies.

Conclusion:

Piet Herdewijn's outstanding work in the field of antiviral research, supported by his impressive list of patents, exemplifies his dedication to improving human health and well-being. His innovative contributions have revolutionized the treatment and prevention of viral infections, particularly those caused by the herpes simplex virus, human cytomegalovirus, varicella-zoster virus, vaccinia virus, adenovirus, and HBV family.

Through his career highlights and collaborations, Herdewijn has not only established himself as a leading figure in the field but also positioned himself as an influential researcher in the domain of antiviral therapies. His groundbreaking inventions continue to shape the future of medical advancements and inspire researchers worldwide to explore new possibilities in combating viral infections.

This text is generated by artificial intelligence and may not be accurate.